Phathom Pharmaceuticals, Inc. PHAT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s cash & equivalents?
- Phathom Pharmaceuticals, Inc. (PHAT) reported cash & equivalents of $180.9M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s cash & equivalents decreased by 14.8% year-over-year, from $212.32M to $180.9M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s cash & equivalents has grown at a -14.7% compound annual growth rate (CAGR), from $287.5M to $129.97M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.